Pfizer Ends Development of Its Obesity Pill
Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level of clinical testing.
The drugmaker said Tuesday that it would stop studying danuglipron after a participant in one of its trials experienced a possible drug-induced liver injury that ended once the person stopped taking the drug.
[time-brightcove not-tgx=”true”]
Danuglipron was in phase three testing, which is generally the last phase of development before a company submits the potential treatment to government regulators for approval.
A company official said in a statement that Pfizer still plans to develop other potential obesity treatments in earlier stages of testing.
Read More: Weight-Loss Drugs Like Wegovy Are Linked to Hair Loss
Obesity treatments have become one of the more promising and lucrative sectors of drug development for pharmaceutical companies. Eli Lilly and Co.’s Zepbound, for instance, brought in nearly $5 billion in..